Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Trial ID or NCT#
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Contact us to find out if this trial is right for you.